Epigenomics, Predictive Biosciences Extend Agreement on Prostate Cancer Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics and Predictive Biosciences today said that Predictive Biosciences will develop a prostate cancer test using the GSTP1 biomarker, under a licensing agreement extension.

The agreement, originally forged in 2009, gave Predictive the option to develop the test using the biomarker. In announcing today that it is executing that option, Predictive added that it will also commercialize the test. In return, Epigenomics will receive a one-time fee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.